TANA VAZNI INDEKSI VA FIB-4 INDEKSI ASOSIDA JIGAR FIBROZLANISHINI ERTA BAHOLASH: ADABIYOTLAR TAHLILI
Keywords:
jigar fibrozlanishi, tana vazni indeksi (BMI), FIB-4 indeksi, metabolik sindrom, invaziv bo‘lmagan diagnostika, adabiyotlar tahlili, erta skriningAbstract
Ushbu maqolada 18 yoshdan katta bemorlarda tana vazni indeksi (BMI) va FIB-4 indeksi o‘rtasidagi o‘zaro bog‘liqlik masalasi jigar fibrozlanishini erta, invaziv bo‘lmagan baholash nuqtayi nazaridan ilmiy adabiyotlar tahlili asosida yoritib beriladi. Zamonaviy tadqiqotlar shuni ko‘rsatadiki, ortiqcha tana vazni va semizlik metabolik buzilishlar orqali jigar parenximasida fibrotik o‘zgarishlarning tezlashuviga olib keladi. FIB-4 indeksi esa oddiy laborator ko‘rsatkichlarga asoslangan holda jigar fibrozlanish darajasini baholash imkonini beruvchi ishonchli skrining vositasi sifatida keng qo‘llanilmoqda. Maqolada BMI oshishi bilan FIB-4 indeksining diagnostik ahamiyati, ularning o‘zaro korrelyatsiyasi hamda klinik amaliyotdagi prognozlash imkoniyatlari tahlil qilinadi. Adabiyotlar tahlili natijalari BMI va FIB-4 indekslarining birgalikda qo‘llanilishi jigar fibrozini erta aniqlash va xavf guruhidagi bemorlarni tanlab olishda samarali yondashuv ekanligini ko‘rsatadi.References
Sterling R.K., Lissen E., Clumeck N. et al.
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection // Hepatology. — 2006. — Vol. 43, № 6. — P. 1317–1325.
Vallet-Pichard A., Mallet V., Nalpas B. et al.
FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection // Hepatology. — 2007. — Vol. 46, № 1. — P. 32–36.
Angulo P., Kleiner D.E., Dam-Larsen S. et al.
Liver fibrosis, but no other histologic features, is associated with long-term outcomes in NAFLD // Gastroenterology. — 2015. — Vol. 149, № 2. — P. 389–397.
Castera L.
Non-invasive assessment of liver fibrosis in chronic hepatitis C // Hepatology International. — 2011. — Vol. 5, № 2. — P. 625–634.
Younossi Z.M., Koenig A.B., Abdelatif D. et al.
Global epidemiology of NAFLD // Hepatology. — 2016. — Vol. 64, № 1. — P. 73–84.
Adams L.A., Lindor K.D.
Nonalcoholic fatty liver disease // Annals of Epidemiology. — 2007. — Vol. 17, № 11. — P. 863–869.
Rinella M.E.
Nonalcoholic fatty liver disease: a systematic review // JAMA. — 2015. — Vol. 313, № 22. — P. 2263–2273.
McPherson S., Hardy T., Henderson E. et al.
Evidence of NAFLD progression from steatosis to fibrosis // Hepatology. — 2015. — Vol. 61, № 5. — P. 1557–1564.
Loomba R., Adams L.A.
Advances in non-invasive assessment of hepatic fibrosis // Gut. — 2020. — Vol. 69, № 7. — P. 1343–1352.
Chalasani N., Younossi Z., Lavine J.E. et al.
The diagnosis and management of NAFLD: practice guidance // Hepatology. — 2018. — Vol. 67, № 1. — P. 328–357.
Eslam M., Sanyal A.J., George J.
MAFLD: a consensus-driven proposal // Gastroenterology. — 2020. — Vol. 158, № 7. — P. 1999–2014.
Bellentani S., Scaglioni F., Marino M. et al.
Epidemiology of non-alcoholic fatty liver disease // Digestive Diseases. — 2010. — Vol. 28, № 1. — P. 155–161.
Bedossa P.
Pathology of non-alcoholic fatty liver disease // Liver International. — 2017. — Vol. 37, Suppl. 1. — P. 85–89.
Friedman S.L.
Mechanisms of hepatic fibrogenesis // Gastroenterology. — 2008. — Vol. 134, № 6. — P. 1655–1669.
Byrne C.D., Targher G.
NAFLD: a multisystem disease // Journal of Hepatology. — 2015. — Vol. 62, № 1. — P. S47–S64.
Shah A.G., Lydecker A., Murray K. et al.
Comparison of noninvasive markers of fibrosis // Clinical Gastroenterology and Hepatology. — 2009. — Vol. 7, № 10. — P. 1104–1112.
Petta S., Di Marco V., Camma C.
Insulin resistance and liver fibrosis // Digestive and Liver Disease. — 2011. — Vol. 43, № 7. — P. 540–546.
Ekstedt M., Hagström H., Nasr P. et al.
Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD // Journal of Hepatology. — 2015. — Vol. 61, № 4. — P. 828–834.
Tsochatzis E.A., Bosch J., Burroughs A.K.
Liver cirrhosis // The Lancet. — 2014. — Vol. 383, № 9930. — P. 1749–1761.
Newsome P.N., Sasso M., Deeks J.J. et al.
FibroScan-AST score for the non-invasive identification of liver fibrosis // Journal of Hepatology. — 2020. — Vol. 72, № 3. — P. 479–487.
Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
Articles published in IQRO — Scientific Methodological Journal are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
Authors retain copyright and grant the journal the right of first publication.
Users may read, download, copy, distribute, print, search, or link to the full texts of articles, provided that the original authors and the journal are properly cited.
Published materials may be used, distributed, and reproduced in any medium, provided that the original work is properly cited.



Uzbekistan
Türkiye
Kazakhstan
Kyrgyzstan
Turkmenistan
Azerbaijan
India
Republic of Korea
Japan
United States of America
Kosovo